Insight Pharma Affiliated Reports Collection Announces Asset Purchase Terms and Agreements Report

NEEDHAM, MASS. – Cambridge Healthtech Institute’s Insight Pharma Affiliated Reports Collection announces the Asset Purchase Terms and Agreements in Pharma, Biotech and Diagnostics Report, published by Current Partnering.

This report provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty assets.

The report focuses on four primary types of asset available for purchase:

      • Business assets - the most common asset exchanging hands. Business assets are in the form of a business unit or subsidiary of a parent company. Common assets include territorial businesses or non-core businesses such as an OTC or diagnostics business, separate from the core business operations

      • Product assets - in the form of marketed product, clinical phase development compound, or drug delivery-compound combination. These assets are commonly available as a result of a merger or change in direction of the selling company. The buyer acquires the asset for global or territorial exploitation. It is often the case that the acquiring company is normally a competitor to the seller, but in this situation the trade is of mutual benefit
      • Royalty assets - where a specialist investment company acquires the rights to future royalty payments in return for payment of a lump sum payment to the licensor for the product
      • Technology assets - where a buyer is acquiring a technology platform, research program, patent portfolio or other intellectual property asset. The acquisition is often due to the technology being surplus to a sellers interests, but may also be as a consequence of a sale of assets in advance of the seller entering liquidation

Key Benefits:

      • In-depth understanding of product and asset purchase deal trends since 2000
      • Analysis of the structure of product and asset purchase agreements with numerous real life case studies
      • Comprehensive access to over 600 actual product and asset purchase contracts entered into by the world’s biopharma companies
      • Detailed access to actual product and asset purchase contracts enter into by the leading fifty bigpharma companies
      • Insight into the payment and deal terms included in a product and asset purchase agreement, together with real world clause examples
      • Understand the key deal terms companies have agreed in previous deals
      • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

For more information and to purchase this Insight Pharma Report, visit:http://www.InsightPharmaReports.com

About Insight Pharma Reports

Insight Pharma Reports are written by experts in consulting and industry who collaborate with us to provide a series of reports that evaluate the salient issues in pharmaceutical technology, business, and therapy markets. Insight Pharma Reports are used by leading pharmaceutical, biotech, diagnostic, consulting, and financial companies to keep abreast of the latest advances in pharmaceutical R&D, their potential applications and business impacts, and their current and future position in the marketplace. Insight Pharma Reports is a division within Cambridge Healthtech Institute. http://www.InsightPharmaReports.com

Insight Pharma Reports offers our Affiliated Reports Collection which provides a repository of additional scientific and business resources. For more information, visithttp://www.insightpharmareports.com/affiliatedreports/

Thomson Reuters Launches Life Sciences Partner Ecosystem to Drive Collaborative R&D Drug Processes

The Intellectual Property & Science division of Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, today announced the launch of its Partner Ecosystem for the life sciences market, a new initiative aimed at enabling access to the company's life sciences information through application-specific solutions developed with third-party partners.

Through the Partner Ecosystem, third party developers take advantage of the Thomson Reuters Cortellis open architecture to access the company's content and technology, creating value-add custom solutions that meet the needs of their customers.  These solutions can include Thomson Reuters market leading ontologies, biological target information and other critical information that supports pharmaceutical business development and competitive intelligence projects.

The flexible approach to information delivery enables companies to integrate Thomson Reuters trusted drug pipeline data seamlessly into a user's workflow, delivering the right information at the point of need so users can make informed decisions more quickly.  In addition, partners gain access to the Cortellis Developer Center, a forum where client and third party developers collaborate to share ideas, best practices, and discuss new applications as well as obtain technical support from Thomson Reuters technology and content experts.

"We understand the important role our partners play in working with us to support the success of our mutual customers.  ThePartner Ecosystem is a step toward providing the  infrastructure and collaboration environment necessary to develop solutions that enable the drug R&D process," said Jon Brett-Harris, executive vice president at Thomson Reuters. "The Partner Ecosystem, alongside our portfolio of other advanced solutions, provides the life sciences industry with the necessary tools and information to help address the challenges it faces."

The Partner Ecosystem web site for developers can be found at

http://cortellis.thomsonreuters.com/partners/. To become a partner, or for any questions, please send an email toLife.Sciences.Partners@thomsonreuters.com, or connect with Thomson Reuters at the Bio-IT World Conference & Expo, April 24-26, in Boston, Massachusetts, at booth 236.

The U.S. Contract Manufacturing Outsourcing Market Revives as Pharmaceutical Companies Increasingly Outsource After the Recession, Finds Frost & Sullivan

The upturn in the fortunes of pharmaceutical companies after the recession is mirrored by the U.S. contract manufacturing outsourcing (CMO) market, which is expected to grow at a compound annual growth rate (CAGR) of 8.3 percent from 2011 to 2016. The sterile segment accounts for the highest share of revenues, with 38.7 percent in 2011, which is expected to rise to 47.5 percent by 2016.

New analysis from Frost & Sullivan's (http://www.pharma.frost.com) Analysis of the United States Contract Manufacturing Outsourcing Market research finds that the market earned revenues of $10.73 billion in 2011 and estimates this to reach$15.97 billion in 2016.

If you are interested in more information on this research, please send an email to Britni Myers, Corporate Communications, atbritni.myers@frost.com, with your full name, company name, job title, telephone number, company email address, company Web site, city, state and country.

"The continued expansion of the U.S. pharmaceuticals industry and the big pharma's increased outsourcing to improve cost structure and focus on core competencies will significantly augment the market's revenue growth," said Frost & Sullivan Consultant Jesse Sullivan. "The pharmaceutical companies that had used their excess capacity during the downturn to retain in-house manufacturing are expected to gradually outsource as the economy improves."

Despite the inclination for pharmaceutical companies to outsource, R&D spending dipped from 2010 to 2011, resulting in fewer drugs being developed and marketed. As the CMO market's revenue inflow is contingent on drug development, the torpid R&D activity has slowed the pace of market development.

"Eleven Indian companies in the top 50 generics manufacturers worldwide" states visiongain report

A new report by visiongain lists 11 Indian companies among the top 50 generic drug manufacturers worldwide.

Five Indian companies (Ranbaxy, Cipla, Dr. Reddy’s, Sun Pharma and Lupin) are in the top 20, the joint-highest representation for any country. While Teva remains the largest player in the industry, with revenues of over $10bn for its generics portfolio in 2011, the competition is growing ever more intense.

Patent expiry represents a great opportunity for generics companies. Strong ambition is shown by manufacturers such as South Africa’s Aspen, India’s Aurobindo, and Japan’s Nichi-Iko (which has a possible top 10 ranking by 2012), for example. Leading companies’ generic drug activities are reviewed in Pharma Leader Series: Top 50 Generic Drug Manufacturers 2012-2022, published in March 2012. Visiongain is a business information provider based in London, UK.

This visiongain study provides revenue forecasts for leading companies during the 2012 to 2022 period. Included in the study are pharma multinationals such as Sanofi, Novartis, Pfizer and Abbott. Multinational pharma companies have followed Novartis’ lead in building generic drug portfolios, and have targeted the emerging national markets for pharmaceuticals. Sanofi’s acquisitions have given it a strong presence in the CEE and Latin American markets. Meanwhile, Abbott has become a big player in the Indian market through acquisitions (pharma sourcing). Generic drugs and emerging national (pharmerging) markets are now leading business areas for expansion by pharmaceutical companies, including world industry leaders.

Novartis Talks About Its Recruitment Process With Local Newspaper

One of the largest employers in North-East Lincolnshire, Novartis, has been speaking to the Grimsby Telegraph about its recruitment process.

Pharmaceutical firm Novartis employs more than 500 people in the Grimsby region and has seen demand for its products soar recently, helping to create jobs in an otherwise bleak economy.

Over the last ten years alone, the 226-acre Grimsby site has received £450 million in investment. The firm’s HR manager, Ian Emerson, said that people from all backgrounds are taken on at Novartis but that as a company it does have several attributes that it likes to see in applicants. Mr Emerson explained, "Our staff need to have the ability to learn.

"Because what we do here is quite unique to the area, people are unlikely to have ever worked in exactly the same kind of environment before. The industry is also constantly changing so it is critical that new employees are willing to develop their skills.”

He added that teamwork is also a valuable attribute to applicants entering the recruitment process at Novartis, as well as motivation to learn new skills and develop in their roles.

Mr Emerson said, “Today we are focusing on the various support functions which exist within the company, including finance, logistics and HR.”

FM contract with the leading provider of information services for the healthcare industry

VINCI Facilities has signed a 5 year FM contract as part of a multi country agreement with IMS Health the leading provider of information services for the healthcare industry.

Based in London, the European Headquarter of IMS Health has a footprint of 110,000 square feet spread over eight floors, comprising mostly of office space along with a restaurant area and car park. In this contract, VINCI Facilities delivers services as cleaning in order to maintain a comfortable and safe working environment for our client, post room, facilities help desk mechanical and electrical maintenance, 24 hours security, reception and health & safety.

The VINCI Facilities engineers’ team on site, allows us to identify and quickly respond to any maintenance issues that may occur within the building.

On this site, VINCI Facilities continues to meet the requirements for ISO 14001:2004 and OHSAS18001:2007, which are respectively an environmental management standard and a standard designs to clarify an organization’s impact on health and safety issues.

International senior supply chain professionals from pharma, biotech and generics industry gather

At LogiPharma Europe 2012 more than 350 pan-European and global senior supply chain professionals will deconstruct, analyse and shape the supply chain trends, strategies and solutions that are setting the pace of change in their industry.


As now more than ever, the supply chain is being seen as a strategic component rather than support service and is driving efficiencies in cost, speeding up response times and freeing up working capital, supply chain leaders take centre stage.

Encompassing a thorough analysis of the most pressing issues in the pharmaceutical end to end supply chain, the event will tackle innovative and controversial topics such as how supply chain leaders can support new product introductions that are fast, successful and deliver commercial success to the business. Panellists will feature amongst others:

- Lotte Frost Jørgensen, Director of Launch Office, Novo Nordisk
- Steven Claus, Head of EU Warehousing, Transportation and Internationals Flights, Teva Pharmaceuticals Europe
- Jørn Mayntzhusen, Senior Manager for Supply Optimisation & Launches, Lundbeck